Monoclonal antibody directed against CD20 antigen
US9234045B2 · kind B2 · utility
4Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 14, 2005 |
| Grant date | Jan 12, 2016 |
| Priority date | — |
| Expiry date | Jul 28, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of FcγRIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.